Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structure–activity relationship and in vivo oral efficacy studies

Show simple item record

dc.contributor.author Dziwornu, Godwin Akpeko
dc.contributor.author Coertzen, Dina
dc.contributor.author Leshabane, Meta Kgaogelo
dc.contributor.author Korkor, Constance M.
dc.contributor.author Cloete, Cleavon K.
dc.contributor.author Njoroge, Mathew
dc.contributor.author Gibhard, Liezl
dc.contributor.author Lawrence, Nina
dc.contributor.author Reader, Janette
dc.contributor.author Van der Watt, Mariette Elizabeth
dc.contributor.author Wittlin, Sergio
dc.contributor.author Birkholtz, Lyn-Marie
dc.contributor.author Chibale, Kelly
dc.date.accessioned 2021-07-21T13:40:25Z
dc.date.issued 2021-04
dc.description.abstract A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structure–activity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 × 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells. en_ZA
dc.description.department Biochemistry en_ZA
dc.description.department Genetics en_ZA
dc.description.department Microbiology and Plant Pathology en_ZA
dc.description.department UP Centre for Sustainable Malaria Control (UP CSMC) en_ZA
dc.description.embargo 2022-04-12
dc.description.librarian hj2021 en_ZA
dc.description.sponsorship The University of Cape Town, South African Medical Research Council and South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) and a NRF Community of Practice on ‘Evaluating Malaria Control Interventions’. en_ZA
dc.description.uri http://pubs.acs.org/loi/jmcmar en_ZA
dc.identifier.citation Dziwornu G.A., Coertzen D., Leshabane M. et al. 2021, 'Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structure–activity relationship and in vivo oral efficacy studies', Journal of Medicinal Chemistry, vol. 64, no. 8, pp. 5198-5215. en_ZA
dc.identifier.issn 0022-2623 (print)
dc.identifier.issn 1520-4804 (online)
dc.identifier.other 10.1021/acs.jmedchem.1c00354
dc.identifier.uri http://hdl.handle.net/2263/80929
dc.language.iso en en_ZA
dc.publisher American Chemical Society en_ZA
dc.rights This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, © 2020 American Chemical Society after peer review and technical editing by the publisher. en_ZA
dc.subject Antiplasmodium en_ZA
dc.subject Antimalarials en_ZA
dc.subject Gametocytes en_ZA
dc.subject Benzimidazole en_ZA
dc.subject Phenolic Mannich bases en_ZA
dc.subject Hemozoin en_ZA
dc.subject Microtubules en_ZA
dc.title Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structure–activity relationship and in vivo oral efficacy studies en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record